Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer
2007
The epidermal growth factor receptor, a transmembrane receptor tyrosine kinase of the erbB family, is expressed in 15-30% of all breast cancers. Anti-epidermal growth factor receptor agent cetuximab is an lgG1 chimeric monoclonal antibody with a potent antitumor activity. Cetuximab competes with ligand binding to the epidermal growth factor receptor ectodomain, resulting in an efficient blockade of tumor-promoting downstream signaling pathways. Large clinical studies recently demonstrated cetuximab synergy with radiotherapy and chemotherapy agent irinotecan. Studies in human breast cancer xenografts showed cetuximab synergy with paclitaxel, a potent mitosis spindle-cell stabilizer. In this report, combined paclitaxel and cetuximab achieved a major reduction of the skin metastases of a heavily pretreated patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) invasive ductal breast carcinoma. Treatment was well-tolerated overall and response was not correlated with the appearance of major cetuximab-induced acneiform rash.
Keywords:
- Molecular biology
- Cetuximab
- Epidermal growth factor
- Cancer research
- Epidermal growth factor receptor
- Estrogen receptor
- Triple-negative breast cancer
- Medicine
- Growth factor receptor inhibitor
- Oncology
- Progesterone receptor
- Internal medicine
- Growth factor receptor
- Paclitaxel
- Monoclonal antibody
- Receptor tyrosine kinase
- Endocrinology
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
31
Citations
NaN
KQI